Share
Market Research Report

CELLULAR IMMUNOTHERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Therapy TypeCAR T-Cell Therapy (Chimeric Antigen Receptor T-cell) · TCR-T Cell Therapy (T-Cell Receptor T-cell) · NK Cell Therapy (Natural Killer cell therapy) · Dendritic Cell Therapy · Tumor-Infiltrating Lymphocytes (TIL) Therapy · Macrophage-Based Cell Therapy · and Others (emerging/novel cell types)
  • By SourceAutologous (patient-derived cells) and Allogeneic (donor-derived cells)
  • By IndicationCancer (Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma), Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)) · Infectious Diseases (Viral Infections (e.g., HIV, HBV, HCV, COVID-19), Bacterial Infections (e.g., tuberculosis)) · Autoimmune Disorders (Multiple Sclerosis, Rheumatoid Arthritis, Type 1 Diabetes) · and Others
  • By Manufacturing ModalityEx Vivo Cell Expansion and In Vivo Engineering
  • By End UserHospitals and Clinics · Specialty Endocrinology and Obesity Centers · Ambulatory Surgical Centers (ASCs) · Home Healthcare Services · and Others (Academic and Research Institutes, etc.)
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In10 Mar 2026
  • Report CodeCMI8447
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)

    • CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
    • TCR-T Cell Therapy (T-Cell Receptor T-cell)
    • NK Cell Therapy (Natural Killer cell therapy)
    • Dendritic Cell Therapy
    • Tumor-Infiltrating Lymphocytes (TIL) Therapy
    • Macrophage-Based Cell Therapy
    • Others (emerging/novel cell types)

  • Source Insights (Revenue, USD Bn, 2021 - 2033)

    • Autologous (patient-derived cells)
    • Allogeneic (donor-derived cells)

  • Indication Insights (Revenue, USD Bn, 2021 - 2033)

    • Cancer
    • Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
    • Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
    • Infectious Diseases
    • Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
    • Bacterial Infections (e.g., tuberculosis)
    • Autoimmune Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Type 1 Diabetes
    • Others

  • Manufacturing Modality Insights (Revenue, USD Bn, 2021 - 2033)

    • Ex Vivo Cell Expansion
    • In Vivo Engineering

  • End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospitals and Clinics
    • Specialty Endocrinology and Obesity Centers
    • Ambulatory Surgical Centers (ASCs)
    • Home Healthcare Services
    • Others (Academic and Research Institutes, etc.)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa